News articles about Zimmer Biomet Holdings (NYSE:ZBH) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet Holdings earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.4167922268304 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Zacks: Analysts Anticipate Zimmer Biomet Holdings, Inc. (ZBH) to Post $1.77 Earnings Per Share (americanbankingnews.com)
- NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite (finance.yahoo.com)
- Zimmer Biomet Holdings to Present at Morgan Stanley 15th Annual Global Healthcare Conference (finance.yahoo.com)
- Consensus score reveals Buy position in Healthcare Stock: Zimmer Biomet Holdings, Inc. (ZBH) – Street Observer (press release) (streetobserver.com)
A number of equities analysts have recently weighed in on ZBH shares. Royal Bank Of Canada increased their price target on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research note on Wednesday, June 21st. Bank of America Corporation reissued a “buy” rating and set a $158.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. BidaskClub lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings currently has an average rating of “Hold” and an average target price of $136.75.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 0.03% during mid-day trading on Friday, reaching $115.70. The company’s stock had a trading volume of 999,596 shares. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The stock has a 50 day moving average of $116.64 and a 200-day moving average of $120.78. The stock has a market cap of $23.39 billion, a P/E ratio of 32.95 and a beta of 1.21.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by $0.02. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.02 earnings per share. On average, equities research analysts expect that Zimmer Biomet Holdings will post $8.24 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.
In other news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Holdings (ZBH) Given News Impact Score of 0.15” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/09/11/zimmer-biomet-holdings-zbh-given-news-impact-score-of-0-15.html.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.